arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CUMBERLAND PHARMACEUTICALS INC

CPIX
$7.83 ▲ +0.19 (+2.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

CUMBERLAND PHARMACEUTICALS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $116.3M
Dividend Yield
Revenue Growth 17.6%
Op. Margin -6.3%
ROIC -8.9%
FCF / Share $0.33
Trailing P/E
Price / Book 4.7x
FCF Yield 4.2%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.52M
↑ +17.6%
Net Income Profit after all expenses
$-2.84M
↑ +56.2%
Operating Margin Operating profit as % of sales
-6.3%
↑ +63.1% 19th
FCF / Share Free cash flow per share
$0.33
↑ +774.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
34
Returns
33
Financial Health
35
Cash Quality
7

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters